Clay B. Siegall is a science expert who is renowned due to the excellent research that he has conducted on cancer. He is a co-founder of a pharmaceutical corporation that is known as Seattle Genetics. Siegall also serves the company as its CEO and president. Since the founding of the enterprise in 1998, it has been dedicated to conducting detailed research, scientific discoveries, and creating new drugs. Clay has been working hard to develop various therapies that be utilized in treating cancer patients. The doctor has played a significant role in the developing antibody-drug conjugates (ADCs) at Seattle Genetics. The first ADC that the company created was called ADCETRIS®. The drug was licensed by the FDA in 2011, and it is currently sold in more than 65 countries. Seattle Genetic collaborated with Takeda Pharmaceutical Company to ensure that ADCETRIS® becomes an international brand. The company’s researchers have been striving to develop different types of ADC that can cure cancer.
Dr. Clay Seigall has assisted his company is getting different strategic licenses that have enabled it to manufacture and supply its drugs on a global scale. The primary medicines that have been developed by the firm include GlaxoSmithKline, AbbVie, Genentech, and Pfizer. The corporation has currently raised revenue of more than $350 million from selling the drugs across the world. Seattle Genetic’s technology has been used in the formation of more than 20 ADCs. The company manufactures the drugs internally and also joins efforts with other corporations to develop them externally. Clay Siegall has established excellent strategies that have assisted the firm in securing funding. It has raised more than $1.2 billion since 2001.
Clay had an opportunity to work for different pharmaceutical firms before he established Seattle Genetics. His first employer was the National Cancer Institute, and he later moved to Bristol-Myers Squibb Pharmaceutical Research Institute. He has also sat on the management boards of corporations such as Washington Roundtable, BioPharmaceutica, and Ultragenyx Pharmaceutical. Siegall is focused on the research that he conducts. He has to date written more than 70 publications and has 15 patents for the products that he has developed.